Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 392 clinical trials
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

Purpose The purpose of this Phase III study is to determine if regorafenib improves overall survival in patients with Advanced Gastro-Oesophageal Carcinoma.

  • 98 views
  • 23 Jan, 2021
  • 50 locations
Total Intravenous Anesthesia and Recurrence Free Survival

The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based

surgery for esophageal cancer
cancer
esophagus cancer
opioid
esophageal cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer

patients with Stage IIB or III squamous cell esophageal carcinoma.

esophagectomy
chemoradiotherapy
cancer treatment
cancer
docetaxel
  • 15 views
  • 24 Jan, 2021
  • 1 location
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.

metastasis
neutrophil count
carcinoma
squamous cell carcinoma
esophageal carcinoma
  • 0 views
  • 25 Jan, 2021
  • 3 locations
Study Compare Adjuvant Chemotherapy Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma

A multi-center prospective randomized controlled study was conducted to compare the effects of adjuvant chemotherapy, chemoradiotherapy and surgery alone for the patients with esophageal cancer

  • 0 views
  • 23 Jan, 2021
  • 1 location
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma

This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

chemoradiotherapy
carcinoma
measurable disease
squamous cell carcinoma
sintilimab
  • 17 views
  • 25 Jan, 2021
  • 11 locations
A Study of Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Cancer of the Esophagus

NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the primary endpoint overall survival and superiority for the experimental intervention definitive chemoradiotherapy with regard to the main secondary endpoint global health related quality of life (HRQOL) one year after randomisation. The aim …

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

  • 0 views
  • 01 Mar, 2021
  • 71 locations
Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), melanoma, urothelial, head and neck, ovarian, gastric (stomach), esophagogastric junction (EGJ), non-small cell lung (NSCLC), or esophageal cancer

gastric cancer
lung carcinoma
cancer
carcinoma
measurable disease
  • 9 views
  • 25 Jan, 2021
  • 17 locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

pembrolizumab
chemoradiotherapy
leucovorin
carcinoma
squamous cell carcinoma
  • 32 views
  • 07 Mar, 2021
  • 131 locations